检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:王会敏 Wang Huimin(Department of Critical Care Medicine,Zhengzhou People’s Hospital,Zhengzhou,Henan,450000,China)
机构地区:[1]郑州人民医院重症医学科,河南郑州450000
出 处:《黑龙江医学》2025年第7期793-795,共3页Heilongjiang Medical Journal
摘 要:目的:探讨肝硬化患者小肠细菌过度生长(SIBO)在胃肠道中的作用。方法:选取2018年9月—2020年1月郑州人民医院消化内科收治的63例乙肝相关性肝硬化患者及同期40名健康体检者作为研究对象。肝硬化患者根据Child-Pugh评分分为A、B、C 3级,比较与对照组胃肠道症状积分的差异;比较肝硬化患者SIBO阳性与阴性的胃肠道症状积分;比较肝硬化SIBO阳性与阴性患者治疗前后及转阴与仍阳性组患者的胃肠道症状积分。结果:肝硬化Child-Pugh A级、B级、C级患者胃肠道症状积分高于健康对照组,差异均有统计学意义(t=7.47、8.27、10.16,P<0.05);肝硬化SIBO阳性患者胃肠道症状积分高于较阴性患者,差异有统计学意义(t=2.23,P<0.05);42例肝硬化SIBO阳性患者经利福昔明治疗后有20例转阴,同时治疗后胃肠道症状积分低于治疗前积分,差异有统计学意义(t=3.46,P<0.05);治疗后SIBO转阴的患者胃肠道症状积分低于SIBO仍阳性患者,差异有统计学意义(t=-2.53,P<0.05)。结论:肝硬化患者易伴发SIBO,SIBO可能是引起肝硬化患者胃肠道症状的原因之一,利福昔明干预后可以部分抑制SIBO,对肝硬化患者的胃肠道症状有一定的缓解作用。Objective:To investigate the role of intestinal bacterial overgrowth in patients with cirrhosis in gastrointestinal tract.Methods:63 patients with cirrhosis and 40 healthy physical examinees were included as the control group.According to the child-pugh score of A,B and C,the difference of digestive tract symptom score was compared with that of healthy control group.Digestive tract symptom scores of SIBO positive and negative were compared in patients with cirrhosis.The score of digestive tract symptoms of patients with SIBO(+)and(-)before and after treatment,and those with negative or still positive were compared.Results:The scores of digestive tract symptoms in grade A,grade B and grade C patients with Child-Pugh cirrhosis were higher than those in healthy control group,and the differences were statistically significant(t=7.47,8.27,10.16;P<0.05).The digestive tract score of the cirrhosis positive group was higher than that of the negative group,and there was statistical difference between the two groups(t=2.23,P<0.05).20 of 42 patients with SIBO positive cirrhosis turned negative after rifaximin treatment,and the score of gastrointestinal symptoms after treatment was lower than that before treatment,and the difference was statistically significant(t=3.46,P<0.05).The score of gastrointestinal symptoms in patients with SIBO turning negative after treatment was lower than that in patients with SIBO remaining positive,and the difference was statistically significant(t=-2.53,P<0.05).Conclusion:Patients with liver cirrhosis are prone to SIBO.It is one of the causes of gastrointestinal symptoms in patients with liver cirrhosis.After intervention with rifaximin,SIBO was partially inhibited.It can relieve gastrointestinal symptoms in patients with cirrhosis.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.7